Solid Biosciences Llc Stock Buy Hold or Sell Recommendation
| SLDB Stock | USD 5.41 0.18 3.44% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Solid Biosciences LLC is 'Strong Sell'. Macroaxis provides Solid Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SLDB positions.
Check out Solid Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Solid and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Solid |
Execute Solid Biosciences Buy or Sell Advice
The Solid recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Solid Biosciences LLC. Macroaxis does not own or have any residual interests in Solid Biosciences LLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Solid Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Solid Biosciences Trading Alerts and Improvement Suggestions
| Solid Biosciences generated a negative expected return over the last 90 days | |
| Solid Biosciences has high historical volatility and very poor performance | |
| Solid Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (96.02 M) with profit before overhead, payroll, taxes, and interest of 13.62 M. | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (94.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Equities Analysts Offer Predictions for SLDB FY2024 Earnings |
Solid Biosciences Returns Distribution Density
The distribution of Solid Biosciences' historical returns is an attempt to chart the uncertainty of Solid Biosciences' future price movements. The chart of the probability distribution of Solid Biosciences daily returns describes the distribution of returns around its average expected value. We use Solid Biosciences LLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Solid Biosciences returns is essential to provide solid investment advice for Solid Biosciences.
| Mean Return | -0.87 | Value At Risk | -8.66 | Potential Upside | 5.73 | Standard Deviation | 4.47 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Solid Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Solid Stock Institutional Investors
| Shares | Finepoint Capital Lp | 2024-06-30 | 961.3 K | Hhg Plc | 2024-06-30 | 753 K | Geode Capital Management, Llc | 2024-06-30 | 513.5 K | Laurion Capital Management Lp | 2024-06-30 | 489.7 K | Monashee Investment Management Llc | 2024-09-30 | 485 K | Silverarc Capital Management, Llc | 2024-06-30 | 473 K | Alyeska Investment Group, L.p. | 2024-06-30 | 446.4 K | Walleye Trading Advisors, Llc | 2024-06-30 | 412 K | State Street Corp | 2024-06-30 | 404.4 K | Perceptive Advisors Llc | 2024-09-30 | 6.9 M | Ra Capital Management, Llc | 2024-06-30 | 4.3 M |
Solid Biosciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (31.5M) | 7.5M | (141.2M) | (182.8M) | 30.5M | 32.0M | |
| Change In Cash | (10.3M) | 78.7M | (33.9M) | 36.0M | (81.4M) | (77.3M) | |
| Free Cash Flow | (97.1M) | (57.5M) | (79.0M) | (101.0M) | (95.7M) | (100.5M) | |
| Depreciation | 2.8M | 3.9M | 3.0M | 2.4M | 2.6M | 2.1M | |
| Other Non Cash Items | (277K) | (20K) | (81K) | (18.3M) | (2.0M) | (2.1M) | |
| Capital Expenditures | 4.4M | 899K | 1.3M | 3.0M | 1.5M | 2.7M | |
| Net Income | (117.2M) | (88.3M) | (72.2M) | (86.0M) | (96.0M) | (100.8M) | |
| End Period Cash Flow | 76.4M | 155.1M | 121.2M | 157.2M | 74.0M | 92.8M | |
| Change To Netincome | 14.2M | 11.6M | 13.5M | 7.5M | 8.7M | 7.7M |
Solid Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Solid Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Solid Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Solid stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.13 | |
β | Beta against Dow Jones | 2.49 | |
σ | Overall volatility | 4.53 | |
Ir | Information ratio | -0.22 |
Solid Biosciences Volatility Alert
Solid Biosciences LLC exhibits very low volatility with skewness of -0.02 and kurtosis of 0.92. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Solid Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Solid Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Solid Biosciences Fundamentals Vs Peers
Comparing Solid Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Solid Biosciences' direct or indirect competition across all of the common fundamentals between Solid Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Solid Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Solid Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Solid Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Solid Biosciences to competition |
| Fundamentals | Solid Biosciences | Peer Average |
| Return On Equity | -0.66 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Current Valuation | 51.78 M | 16.62 B |
| Shares Outstanding | 39.95 M | 571.82 M |
| Shares Owned By Insiders | 0.81 % | 10.09 % |
| Shares Owned By Institutions | 90.06 % | 39.21 % |
| Number Of Shares Shorted | 1.48 M | 4.71 M |
| Price To Book | 1.19 X | 9.51 X |
| Price To Sales | 3.65 X | 11.42 X |
| Gross Profit | 13.62 M | 27.38 B |
| EBITDA | (93.43 M) | 3.9 B |
| Net Income | (96.02 M) | 570.98 M |
| Cash And Equivalents | 162.88 M | 2.7 B |
| Cash Per Share | 1.44 X | 5.01 X |
| Total Debt | 26.27 M | 5.32 B |
| Debt To Equity | 0.15 % | 48.70 % |
| Current Ratio | 7.85 X | 2.16 X |
| Book Value Per Share | 4.29 X | 1.93 K |
| Cash Flow From Operations | (94.18 M) | 971.22 M |
| Short Ratio | 4.44 X | 4.00 X |
| Earnings Per Share | (3.04) X | 3.12 X |
| Target Price | 17.43 | |
| Number Of Employees | 88 | 18.84 K |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 208.96 M | 19.03 B |
| Total Asset | 164.94 M | 29.47 B |
| Retained Earnings | (658.75 M) | 9.33 B |
| Working Capital | 115.22 M | 1.48 B |
| Net Asset | 164.94 M |
Note: Disposition of 9750 shares by Brooks Gabriel of Solid Biosciences subject to Rule 16b-3 [view details]
Solid Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Solid . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 29439.53 | |||
| Daily Balance Of Power | 0.439 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 5.42 | |||
| Day Typical Price | 5.41 | |||
| Price Action Indicator | 0.085 | |||
| Period Momentum Indicator | 0.18 |
About Solid Biosciences Buy or Sell Advice
When is the right time to buy or sell Solid Biosciences LLC? Buying financial instruments such as Solid Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Solid Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Solid Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.